SDC3 as a Radioligand Therapy Target
SDC3, syndecan 3, is a cell-surface protein. In Human Protein Atlas immunohistochemistry, SDC3 staining is highest in thyroid cancer (100% of samples positive), testicular cancer (100% of samples positive) and bladder cancer (100% of samples positive). Clinical status: Discovery-stage (no clinical drug program).
Is SDC3 a good radioligand therapy target?
Scored against the six criteria that decide whether a protein can become a radioligand therapy:
- ✅ Cell-surface accessibility: Localized to the cell surface, so a radioligand can reach it from circulation.
- ✅ Tumor expression: High IHC staining in thyroid cancer, 100% of samples positive.
- ❔ Internalization: Not yet assessed.
- ⚠️ Clinical precedent: Discovery-stage (no clinical drug program)
- ❔ Shedding: Not yet assessed.
- ❔ Normal-tissue dosimetry: Check kidney, liver, bone marrow and salivary expression in the Human Protein Atlas tissue atlas.
SDC3 expression in cancer
Protein expression of SDC3 across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.
| Cancer type | IHC score | Level | % positive |
|---|---|---|---|
| Thyroid Cancer | 0.67 | High | 100% |
| Testicular Cancer | 0.60 | High | 100% |
| Bladder Cancer | 0.55 | High | 100% |
| Kidney Cancer | 0.53 | High | 100% |
| Cervical Cancer | 0.47 | Medium | 92% |
| Breast Cancer | 0.44 | Medium | 92% |
| Neuroendocrine Tumors | 0.42 | Medium | 75% |
| Skin Cancer | 0.39 | Medium | 91% |
| Colorectal Cancer | 0.39 | Medium | 83% |
| Ovarian Cancer | 0.39 | Medium | 75% |
| Liver Cancer | 0.36 | Medium | 73% |
| Endometrial Cancer | 0.36 | Medium | 83% |
| Head and Neck Cancer | 0.33 | Medium | 75% |
| Lung Cancer | 0.33 | Medium | 67% |
| Pancreatic Cancer | 0.31 | Medium | 83% |
| Prostate Cancer | 0.31 | Medium | 75% |
| Glioma | 0.31 | Medium | 75% |
| Gastric Cancer | 0.30 | Medium | 82% |
| Lymphoma | 0.17 | Low | 42% |
| Melanoma | 0.14 | Low | 42% |
Is SDC3 internalized?
Nuclens has not yet extracted internalization evidence for SDC3. Internalization matters for radioligands because an internalizing receptor traps the radionuclide inside the tumor cell. Run a full analysis to pull the latest literature.
SDC3 clinical trials
Discovery-stage (no clinical drug program). Nuclens hasn't indexed trials for SDC3 yet. Search ClinicalTrials.gov for SDC3 trials.
SDC3 normal tissue expression
Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See SDC3 in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.
SDC3 gene essentiality (DepMap)
CRISPR knockout effect across 1258 cancer cell lines: -0.05 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.
Related thyroid cancer radioligand targets
c-MET (MET) · HER3 (ERBB3) · EPCAM · SSTR2 · EGFR · ITGAV · STEAP2 · FAP
See all radioligand therapy targets in thyroid cancer.
See how SDC3 ranks against 15,000 targets for your indication.
Run a free analysisData sources
Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.